InterCure Ltd. Form 6-K Summary
Business Context and Reporting Period
InterCure Ltd., an Israeli foreign private issuer, filed Form 6-K on April 3, 2023, covering the month of April 2023. The filing includes materials related to the year ended December 31, 2022, including a press release dated March 31, 2023, management’s discussion and analysis, consolidated financial statements, and the 2022 Annual Information Form.
Financial Metrics
The provided filing text identifies the financial statement exhibits but does not include their underlying financial data. Accordingly, the text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes Versus the Prior Comparable Period
The filing excerpt does not describe material year-over-year changes. Comparative information may be included in Exhibits 99.2 and 99.3, but those exhibits are not reproduced in the provided text.
Guidance, Outlook, Risks, and Unusual Items
The filing excerpt does not provide clear guidance, outlook statements, management commentary, risk disclosures, contingencies, or unusual items. These matters may be addressed in the incorporated exhibits, particularly the press release, MD&A, and Annual Information Form.
Investor Verification Items
- Review Exhibit 99.1 for the March 31, 2023 press release and any operating or financial updates.
- Review Exhibit 99.2 for management’s discussion of results, liquidity, capital resources, trends, and risks for the year ended December 31, 2022.
- Review Exhibit 99.3 to verify revenue, profitability, cash flow, balance-sheet, debt, and liquidity figures.
- Review Exhibit 99.4 for the company’s business description, risk factors, regulatory matters, and other annual disclosures.
- Confirm whether the complete exhibits contain guidance, contingencies, related-party matters, or subsequent events not included in this filing excerpt.